| 0.9301 -0.006 (-0.59%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.27 | 1-year : | 1.48 |
| Resists | First : | 1.09 | Second : | 1.27 |
| Pivot price | 0.88 |
|||
| Supports | First : | 0.86 | Second : | 0.73 |
| MAs | MA(5) : | 0.92 |
MA(20) : | 0.88 |
| MA(100) : | 1.97 |
MA(250) : | 4.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 73.3 |
D(3) : | 74 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 11.89 | Low : | 0.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AXDX ] has closed below upper band by 29.1%. Bollinger Bands are 76.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 56 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.95 | 0.95 - 0.96 |
| Low: | 0.87 - 0.88 | 0.88 - 0.88 |
| Close: | 0.92 - 0.93 | 0.93 - 0.94 |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Sat, 20 Apr 2024
Accelerate Diagnostics (AXDX) Jumps: Stock Rises 9.4% - Yahoo Movies UK
Tue, 16 Apr 2024
Accelerate Diagnostics CEO sells shares worth over $22k - Investing.com
Thu, 28 Mar 2024
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 28 Mar 2024
Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 27 Mar 2024
Accelerate Diagnostics Inc (AXDX) Stock Loses -2.02% This Week; Should You Buy? - InvestorsObserver
Fri, 19 Jan 2024
US Stocks Higher; Schlumberger Earnings Beat Estimates - Accelerate Diagnostics (NASDAQ:AXDX), C3is (NASD - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 22 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 37.1 (%) |
| Held by Institutions | 12.7 (%) |
| Shares Short | 293 (K) |
| Shares Short P.Month | 299 (K) |
| EPS | -4.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.38 |
| Profit Margin | 0 % |
| Operating Margin | -354.5 % |
| Return on Assets (ttm) | -70.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 1.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.55 |
| EBITDA (p.s.) | -2.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | -0.1 |
| Price to Book value | -0.68 |
| Price to Sales | 1.67 |
| Price to Cash Flow | -0.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|